Access cutting-edge lung cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Sponsor: BioNTech SE
Check if you qualify for this lung cancer clinical trial in New York, NY
If you're searching for lung cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.